Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Open-Label, Dose-Escalation and Expansion Phase Ib/II Study to Evaluate the Safety, PK, and PD of Multiple Ascending Doses of HZBio1 in Patients With Gout

NCT07752810 is registered in ClinicalTrials.gov with Hangzhou Grand Biologic Pharmaceutical, Inc. as lead sponsor.

NCT NCT07752810
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07752810 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Open-Label, Dose-Escalation and Expansion Phase Ib/II Study to Evaluate the Safety, PK, and PD of Multiple Ascending Doses of HZBio1 in Patients With Gout
Lead sponsor
Hangzhou Grand Biologic Pharmaceutical, Inc.
Phase
Phase 1/2
Overall status
Completed
Start date
June 23, 2022
Completion date
May 19, 2025
Enrollment
90 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

gout